French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and South African biopharmaceutical company Biovac on Thursday announced a partnership to produce inactivated polio vaccines (IPV) in Africa.
This initiative aims to serve over 40 African countries and positions Biovac as the continent's first IPV manufacturer.
Sanofi will continue bulk production, while Biovac will handle final formulation, filling, packaging and distribution of millions of doses to UNICEF for GAVI countries in Africa. This collaboration aligns with the Africa Centers for Disease Control and Prevention's goal of 60% local vaccine production by 2040.
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate